ストックスクリーナーアプリを入手
0.8563
0.86%
-0.0074
アフターアワーズ：
.85
-0.0063
-0.74%
前日終値:
$0.8637
開ける：
$0.8829
24時間の取引高:
69,024
Relative Volume:
0.47
時価総額：
$13.68M
収益：
-
当期純損益:
$-43.10M
株価収益率:
-0.1379
EPS:
-6.2098
ネットキャッシュフロー:
$-26.38M
1週間 パフォーマンス:
-7.52%
1か月 パフォーマンス:
-22.86%
6か月 パフォーマンス:
-68.52%
1年 パフォーマンス:
-76.31%
1日の値動き範囲:
$0.8526
$0.8878
1週間の範囲:
$0.8401
$0.9784
52週間の値動き範囲:
$0.8401
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
名前
Tempest Therapeutics Inc
セクター
電話
415-798-8589
住所
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.8563 | 14.93M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-02-08 | 開始されました | Jefferies | Buy |
Tempest Therapeutics Inc (TPST) 最新ニュース
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Tempest Therapeutics Inc (TPST) Cash Flow - TradingKey
TPST|Tempest Therapeutics Inc|Price:0.942|Chg%:+0.016 - TradingKey
TradingKey - TradingKey
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks
Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com
Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et
TPST|Tempest Therapeutics Inc|Price:0.930| - TradingKey
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases - Quiver Quantitative
Tempest Announces Development Collaboration with Senlang - GlobeNewswire
Tempest Therapeutics (TPST) plans vote on supermajority and written-consent changes - Stock Titan
William Drake Richey Net Worth (2026) - GuruFocus
Tempest advances next-generation in vivo CAR T pipeline - BioWorld News
Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com - Investing.com South Africa
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial - Quiver Quantitative
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, - GlobeNewswire
Tempest's planned CAR-T study targets myasthenia gravis and MS - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants - Stock Titan
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter - Stock Titan
Tempest Therapeutics (TPST) Edges Lower as Stock Hovers Near Key Support LevelDiamond Pattern - dars.gov.et
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
TPST Q1 2026 Earnings: Deep EPS Miss as Clinical-Stage Biotech Reports $2.53 Loss Per ShareEarnings Growth Analysis - DonanımHaber
Tempest Therapeutics (TPST) Rallies Modestly as Stock Holds Above Key SupportMomentum ETF - dars.gov.et
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - GlobeNewswire
Tempest Therapeutics Registers 2.43 Million Shares for Resale - Moomoo
Form S-3 Tempest Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
TPST Forecast — Price Target — Prediction for 2027 - TradingView
TPST: Selling Stockholders Plan to Offer 2.43 Million Shares - GuruFocus
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants - Stock Titan
3OS0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Price to sales forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBITDA forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST) - TradingView
Price to earnings forward of Tempest Therapeutics, Inc. – LS:A41556 - TradingView
Enterprise value to EBIT forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
Form 4 Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock By Investing.com - Investing.com South Africa
Tempest Therapeutics CEO Matthew Angel acquires $500,001 in stock - Investing.com
CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants - Stock Titan
Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares By Investing.com - Investing.com South Africa
Form 8K Tempest Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) 財務データ
収益
当期純利益
現金流量
EPS
Tempest Therapeutics Inc (TPST) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Angel Matthew | CEO and President |
Mar 24 '26 |
Buy |
2.16 |
231,482 |
500,001 |
231,482 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):